Article
Nitrosamine Testing: The Regulatory Aspects
Author(s):
Detection of N-Nitrosodimethylamine (NDMA) impurities has led to regulatory warnings and product recalls. Pharmaceutical manufacturers must adopt a proactive approach to risk assessment and mitigation in relation to genotoxic contaminants.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
